PATIENTS AND CAREGIVERS
Your journey with
Immuneel’s CAR T-Cell
therapy.
Welcome to CellSpectrum. Here you will find valuable information to resources that can assist you. CAR T-Cell Therapy is approved for the treatment of Relapsed / Refractory B Cell Non-Hodgkin Lymphoma (B-NHL).
Overview of B Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)
- Originates in the lymphatic system, which is a part of the body’s immune system.
- Can spread to other parts of the body through the lymphatic vessels or bloodstream.
What is CAR T-cell therapy?
CAR T-cell therapy is a novel treatment to fight some cancers. It involves using your body’s own immune system to treat your cancer. CD-19 CAR T-cell therapy has been a standard of care for Relapsed / Refractory B Cell Non-Hodgkin Lymphoma in the West since 2017. Based on the recently published evidence, CD-19 targeted CAR T-cell therapy is now the preferred second line therapy for Relapsed / Refractory B Cell Non-Hodgkin Lymphoma.
Seven steps in
CAR T-Cell therapy
Is CAR T-cell therapy the right treatment for you?
- A novel treatment option with a potential to cure B-NHL. Overall, CAR T-cell therapy represents a significant advancement in the treatment of B-NHL by offering a targeted, personalised approach that has demonstrated high responses, durable remissions, and improved long-term outcomes for patients who have limited or no treatment options.
- Please consult a Hemato-oncologist / Oncologist if CAR T-cell therapy is appropriate for you.
Please refer the Guides for you to initiate the discussion with your doctor. Download the guides.
Frequently asked questions
Before reaching out for support, we recommend checking our comprehensive Frequently Asked Questions (FAQ) section. In case your queries are not answered, please contact us.
CHECK FAQ'SFor more information, please reach out to your treating doctor.
Active participation in your healthcare journey will enable you to make informed decisions.
